The East-West Bio Brief
af Basil Lui
Daily, Sat 14 Nov: Can a Chinese cancer drug win over the FDA?
Om denne podcast
Biotech and beyond, from China, Asia and the West. Over half of global biotech licensing value now comes from China, and the first signal often shows up in Chinese. Basil Lui and Ning turn primary sources into what matters for deals: a daily brief Tuesday to Sunday and a weekly roundup on Mondays. Beyond Biotech covers health tech, diagnostics, AI drug discovery, lab automation, pet care and wearables. For BD teams, VCs and family offices.
https://eastwestbiobrief.com
Both voices are AI-cloned. Basil Lui is the real person behind the show; Ning is an AI co-host. Not investment advice.
Episoder
- Daily, Sat 14 Nov: Can a Chinese cancer drug win over the FDA? · 11 min.This episode covers the FDA's target date for ivonescimab, a lung cancer bispecific invented by Akeso (康方生物) and licensed to Summit Therapeutics. The global HARMONi trial met its…
- Daily, Fri 13 Nov: The first personalised mRNA cancer vaccine to succeed in Phase 3 · 12 min.Moderna and Merck's personalised mRNA cancer vaccine intismeran autogene (mRNA-4157/V940) plus Keytruda is the first positive Phase 3 result for a personalised neoantigen…
- Daily, Thu 12 Nov: A Shanghai pill wins FDA approval, after China said yes first · 14 min.This episode covers Abbisko's pimicotinib (Pimjetmi), FDA-approved for tenosynovial giant cell tumour after China, Canada and Switzerland, on a trial with almost half its…
- Daily, Wed 11 Nov: Who will own the labs that test new medicines across the Pacific? · 12 min.This episode covers Charles River, Tigermed and Frontage's chairman taking Hong Kong-listed Frontage private and selling its Pennsylvania testing labs to Charles River; a…
- Daily, Tue 10 Nov: A Chinese firm comes off a Pentagon list. Is the risk gone? · 11 min.This episode covers the US Defense Department's removal of WuXi AppTec from its 1260H list and what it does not settle, two Chinese antibody–drug conjugates in EGFR-mutated lung…
- Weekly, Mon 9 Nov: A survival win, a billion-dollar deal, an Ebola push. What's real? · 23 min.Akeso’s ivonescimab, Genrix’s early lupus data and Ebola vaccine candidates: evidence, money and delivery across this week’s East–West biotech news. China review is not approval…
- Daily, Sun 8 Nov: When a better blood marker doesn't help patients · 12 min.This episode covers Akeso's ivonescimab priority review in China, new HORIZON and ZEUS cardiovascular trial details, and earlier Asian research on Kylo-11 and tocilizumab. Plus…
- Daily, Sat 7 Nov: Beijing gets its first CAR-T cancer therapy · 11 min.Today's East-West Bio Brief daily covers ImunoPharm's Sai Bo Hua CD19 CAR-T approval (China's tenth, Beijing's first); Bio-Thera's golimumab biosimilar; China-out deals…
- Daily, Fri 6 Nov: China approves a first-of-its-kind stroke-prevention pill · 10 min.Today's East-West Bio Brief daily covers China's approval of Bayer's asundexian (Sunharbo), the world's first Factor XIa inhibitor for stroke risk reduction; Qyuns Therapeutics…
- Daily, Thu 5 Nov: A Hong Kong biotech IPO hits pause · 6 min.Today's East-West Bio Brief daily covers Hemay Pharma postponing its Hong Kong listing for mufemilast, its psoriasis pill; Boehringer Ingelheim's option deal with Sino Biopharm…
- Daily, Wed 4 Nov: Did Beijing tell banks to pause new listings? · 7 min.Today's East-West Bio Brief daily covers a Financial Times report, not confirmed by the regulator, that China's securities regulator told banks to pause IPOs; Hemay Pharma's Hong…
- Daily, Tue 3 Nov: A German group signs a Chinese partner for up to 37 cheaper biologics · 6 min.Today's East-West Bio Brief daily covers Fresenius's exclusive deal with WuXi Biologics for up to 37 biosimilars, first copying Roche's Polivy (lymphoma) and Amgen's Tepezza…
- Daily, Mon 2 Nov: A Chinese cancer drug beat the standard, in China · 5 min.Today's East-West Bio Brief daily covers a China-only trial at ESMO where Akeso's ivonescimab plus chemo beat AstraZeneca's durvalumab plus chemo on survival in first-line…
- Pilot: Why China drove most drug-licensing deal value this year · 13 min. · Episode 1In the first episode of The East-West Bio Brief, we read China's primary sources and translate them into what they mean for deals. We cover Beijing's draft export controls on…








